Clinical trials: Schizophrenic Patients
Schizophrenia, First-Episode
Optimization of Acute Treatment in First Episode Schizophrenia
The study is a multicenter, double-blind, randomized, parallel-group study with first episode schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with Risperidone or Haloperidol.
- Trial name
- NCT00157378
- Testing
- Risperidone, Haloperidol
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Schizophrenia
Efficacy Study on Cognitive Functions in Schizophrenic Patients
Primary objectives To compare neurocognitive effects of amisulpride with those of risperidone in patients with chronic schizophrenia, as assessed by the general cognitive index, a measure of overall cognitive functioning in…
- Trial name
- AMIMIND (NCT00761670)
- Testing
- amisulpride and risperidone
- Where
- Hungary
- Volunteers
- 37 people
- Sponsor
- Sanofi
Schizophrenia
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
- Trial name
- MOZART (NCT00649844)
- Testing
- Clozapine, Ziprasidone
- Where
- 22 sites in Italy
- Volunteers
- 147 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Extrapyramidal Syndrome
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00331825
- Testing
- Risperidone and Olanzapine
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Schizophrenia
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.
- Trial name
- NCT00085891
- Testing
- Quetiapine Fumarate
- Where
- 29 sites in United States
- Volunteers
- 535 people
- Sponsor
- AstraZeneca
Schizophrenia; Psychosis, Remission
Effects of an Interpersonal Communication Skills Training Program on Medication Adherence of Schizophrenic Patients
This quasi-experimental two-group pretest-posttest study examined the effects of an interpersonal communication skills training program on medication adherence in patients with schizophrenia, measured at pre-intervention…
- Conditions
- Schizophrenia; Psychosis, Remission, Non-Adherence, Medication
- Trial name
- NCT07165821
- Testing
- Interpersonal Communication Skills Training Program, Usual care
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Suranaree University of Technology
Schizophrenia, Bipolar
Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine
The goal of this research is investigating the heart rate changes in schizophrenic and bipolar patients under the medication of aripiprazole and quetiapine.
- Trial name
- HeartAriQue (NCT01047215)
- Testing
- Aripiprazole; Quetiapine
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning
Interventional, multicenter, and longitudinal study, of a cohort of patients with schizophrenia, evaluated on social cognition, neurocognition, symptoms, functioning with 12 months interval.
- Trial name
- EVACO (NCT02901015)
- Testing
- Assessment battery A, Assessment battery B
- Where
- 8 sites in France
- Volunteers
- 173 people
- Sponsor
- Versailles Hospital
Schizophrenia
Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia
The purpose of this study is to test the effect of modafinil on the negative symptoms, such as blunted affect and social withdrawal, of schizophrenic patients and to determine modafinil's effect on excessive daytime sleepiness.
- Trial name
- NCT00546403
- Testing
- Modafinil
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia, Depression
Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation)
Muscle evoked potentials (MEP) are supposed to different in schizophrenic and depressed patients, compared to a sample of healthy volunteers.
- Trial name
- NCT01150734
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Foetal Differences Between Healthy and Schizophernic Parents
Schizophrenia Imaging
Schizophrenia is a common disorder with a lifetime prevalence of about 1%.Genetic studies strongly suggest a genetic component to the inheritance of schizophrenia.
- Trial name
- NCT01655472
- Testing
- imaging follow up: MRI scan, imaging follow up: Ultrasonographic examination
- Where
- 8 sites in Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Schizophrenia
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine.
- Trial name
- NCT00056498
- Testing
- Risperdal
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenic Patients
Changes in Brain Synchronization During Perceptual and Linguistic Tasks in Schizophrenic Patients
This study aims to identify electrophysiological correlates of impaired perceptual and linguistic processes in chronic schizophrenic patients, un-medicated first-episode schizophrenic patients and their healthy relatives.
- Trial name
- NCT01550211
- Testing
- Magnetoencephalograph (MEG)
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Schizophrenia, Schizo-Affective Disorder
Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol Levels
The importance of stress as a possible deteriorating factor for schizophrenic patients is well documented. However, this notion is based on subjective experience and retrospective psychological analysis.
- Trial name
- NCT01754532
- Testing
- Hair Sample
- Where
- Israel
- Volunteers
- 34 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
The primary objective of the study is to evaluate the efficacy of quetiapine fumarate (Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from…
- Trial name
- NCT00428350
- Testing
- Quetiapine Fumarate (Seroquel)
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Schizophrenia
The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia
The present study will specify and delineate the separate components of cognitive deficits and examine the effects of adjunctive cholinergic augmentation on these cognitive deficits as well as psychopathology in schizophrenic…
- Trial name
- NCT00206947
- Testing
- donepezil (5-10 mg/day)
- Where
- 4 sites in Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Auditory Hallucinations in Patients With Schizophrenic Disorders
High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled Study
Background: Repetitive transcranial magnetic stimulation (rTMS) is a recent therapeutic which has demonstrated its efficacy in the treatment of auditory hallucinations in patients with schizophrenic disorders.
- Trial name
- TMS-Hz (NCT01022489)
- Testing
- Transcranial magnetic stimulation: rTMS
- Where
- France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Caen
Auditory Hallucinations
Transcranial Magnetic Stimulation (TMS) for Treatment of Auditory Hallucinations
Transcranial magnetic stimulation (TMS) involves the use of magnetic fields to non-invasively stimulate the brain. Studies overseas have suggested this may be an effective and safe treatment for auditory hallucinations in…
- Trial name
- NCT00763841
- Testing
- Transcranial magnetic stimulation
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- The University of New South Wales
Schizophrenia, Metabolic Syndrome X
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
- Trial name
- MESSAGE (NCT00448630)
- Testing
- No intervention
- Where
- 47 sites in Turkey (Türkiye)
- Volunteers
- 328 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.